AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 241 min read$ARQT

Curran Terrie sold $28K of ARQT

Curran Terrie sold 1,072 shares of Arcutis Biotherapeutics, Inc. (ARQT) at $26.04 on 2026-08-20.

Original reporting
SEC EDGAR · Curran Terrie
Published Aug 24, 2026, 8:19 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 24, 2026, 8:30 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$ARQT
Neutral
high confidence
Mentioned
$ARQT
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ARQTNeutralLow
01

Why it matters

The disclosed sale is modest and unlikely to move the stock significantly.

02

Market read

Minor insider sale with limited trading relevance.

03

What to watch

Potential upcoming corporate actions or clinical data releases could affect future insider behavior.

Relevance 3/10Novelty 4/10Timing: filed today

Background

Form 4 filings disclose insider transactions; traders monitor for signals of confidence or concern.

Company-level read

Ticker impact

$ARQTNeutralHigh confidence
Context

Director Curran Terrie sold 1,072 shares for $27,912, reducing his stake to 23,526 shares.

Expected impact

Minimal downward pressure, likely negligible.

Evidence & confidence

Sale size is small relative to market cap and typical insider activity.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

Sale may signal insider concerns, but size is too small to infer material issues.

Key entities

  • Company
    Arcutis Biotherapeutics, Inc.

    Biotech firm developing treatments for skin disorders.

  • Individual
    Curran Terrie

    Director of Arcutis Biotherapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

ARQT insider trading history →

Related articles

AUG 5
$ARQTHigh

Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update

Arcutis Biotherapeutics, Inc. (ARQT) filed an SEC Form 8-K — Results of Operations and Financial Condition. Arcutis Announces Second Quarter 2026 Financial Results and Provides Business Update • Continued strong ZORYVE® (roflumilast) net product revenue growth, with Q2 revenues of $129.9 million, +59% versus Q2 of 2025, and +23% versus Q1 of 2026, driven primarily by strong demand grow

SEC EDGAR 8-K6 min
JUL 8
$ARQTMedAI 8/10

FDA Accepts Supplemental New Drug Application for Arcutis’ ZORYVE® (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months

Arcutis Biotherapeutics (Nasdaq: ARQT) said the FDA accepted its supplemental NDA for ZORYVE (roflumilast) cream 0.05% to expand use for mild to moderate atopic dermatitis in infants aged 3 to 24 months. The FDA set a PDUFA target action date of Feb. 23, 2027. Data cited include Phase 2 INTEGUMENT-INFANT (101 infants) and Phase 1 PK (19 infants).

manilatimes.net5 min
OCT 7
$LWAYLow

Divisadero Street Capital Management, LP (Zolezzi William) purchased $2.2M of LWAY (indirect holdings)

Divisadero Street Capital Management, LP purchased 103,684 indirectly-held shares of Lifeway Foods, Inc. (LWAY) at an average of $20.92 ($20.80–$21.09, $2.17M total) across 3 trades over 2026-10-02 to 2026-10-06. Filed jointly with Divisadero Street Partners GP, LLC (10% owner), Zolezzi William (10% owner), Divisadero Street Partners, L.P. (10% owner) and Divisadero Street Capital, LLC (10% owner).

SEC EDGAR1 min